Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from theMATCHstudy
Open Access
- 1 January 2021
- journal article
- research article
- Published by Wiley in LUTS: Lower Urinary Tract Symptoms
- Vol. 13 (1) , 98-107
Abstract
Objectives To investigate the cardiovascular safety of mirabegron add-on treatment to tamsulosin in male patients with residual overactive bladder symptoms. Methods This was a post hoc analysis of MATCH, the first double-blind, placebo-controlled study comparing mirabegron and placebo as add-on therapy to tamsulosin for treatment of overactive bladder in men with lower urinary tract symptoms. The analysis focused on treatment-emergent adverse events relating to the cardiovascular system or blood pressure, and changes in vital signs during 12 weeks of follow-up. Results Cardiovascular-related treatment-emergent adverse events were reported by 6/566 patients, although only one serious treatment-emergent adverse event was related to treatment (unstable angina in the tamsulosin + placebo group). Hypertension (two patients) and increased blood pressure (one patient) were reported in the tamsulosin + placebo group, but there were no blood pressure-related treatment-emergent adverse events among tamsulosin + mirabegron patients. There were no clinically meaningful changes from baseline in blood pressure, and changes in pulse rate were small (+1.2 bpm in the tamsulosin + mirabegron group). Increased pulse rate was more frequent with tamsulosin + mirabegron than with tamsulosin + placebo in older patients, although within the normal range. Conclusions Cardiovascular-related adverse events were uncommon in both treatment groups. Mirabegron is a well-tolerated add-on therapy to tamsulosin in Japanese and Korean males with residual overactive bladder symptoms.Keywords
Funding Information
- Astellas Pharma US
This publication has 28 references indexed in Scilit:
- Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross‐sectional, population‐based studyLUTS: Lower Urinary Tract Symptoms, 2017
- Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in AsiaExpert Review of Clinical Pharmacology, 2016
- Autonomic and endocrine control of cardiovascular functionWorld Journal of Cardiology, 2015
- Mirabegron in overactive bladder: A review of efficacy, safety, and tolerabilityNeurourology and Urodynamics, 2013
- Presence of central nervous system, cardiovascular and overall co‐morbidity burden in patients with overactive bladder disorder in a real‐world settingBJU International, 2011
- Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladderBJU International, 2010
- β3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ currentJournal of Clinical Investigation, 2008
- An epidemiological survey of overactive bladder symptoms in JapanBJU International, 2005
- Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M 2 or M 3 muscarinic acetylcholine receptorsThe FASEB Journal, 2004
- β1‐, β2‐ and atypical β‐adrenoceptor‐mediated relaxation in rat isolated aortaBritish Journal of Pharmacology, 2000